

FIG. 1

PXRD pattern of the crystalline form of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea L-lactate from Example 4, Preparation A




FIG. 2

re. European Pharmacopoeia Method 2.9.20: "Figure 2.9.20.-1. – Apparatus for visible particles"




FIG. 3



Chromatogram of Blank Solution (Diluent) at Full Scale

FIG. 4

Expanded Chromatogram of Blank Solution (Diluent)

NOTE: Chromatogram solvent peak and system peak can be instrument dependent.